Brief: Lantern Pharma Receives FDA Clearance Of IND Application For LP-184
12/06/2023 15:08
June 12 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA RECEIVES FDA CLEARANCE OF IND APPLICATION
FOR
DRUG CANDIDATE LP-184 IN SOLID TUMORS
* LANTERN PHARMA INC - FIRST-IN-HUMAN PHASE 1A TRIAL FOR
LP-184 IS
ANTICIPATED TO LAUNCH AND DOSE ITS FIRST PATIENT DURING CURRENT
QUARTER
Source text for Eikon: ID:nBw3Kd67qa
Further company coverage: LTRN.O
(reuters.briefs@thomsonreuters.com)
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview